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OBJECTIVE — Transplantation of insulin-producing cells placed inside microcapsules is
being trialled to overcome the need for immunosuppressive therapy.
RESEARCH DESIGN AND METHODS — Four type 1 diabetic patients with no de-
tectable C-peptide received an intraperitoneal infusion of islets inside microcapsules of barium
alginate (mean 178,200 islet equivalents on each of eight occasions).
RESULTS — C-peptide was detected on day 1 post-transplantation, and blood glucose levels
and insulin requirements decreased. C-peptide was undetectable by 1–4 weeks. In a multi-islet
recipient, C-peptide was detected at 6 weeks after the third infusion and remains detectable at
2.5years.Neitherinsulinrequirementsnorglycemiccontrolwasaffected.Capsulesrecoveredat
16monthsweresurroundedbyﬁbroustissueandcontainednecroticislets.Nomajorsideeffects
or infection occurred.
CONCLUSIONS — While allografting of encapsulated human islets is safe, efﬁcacy of the
cells needs to improve for the therapy to make an impact on the clinical scene.
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T
ransplantation of insulin-producing
cellsplacedinsidecapsulesisastrat-
egythatisbeingtrialledtoovercome
the need for immunosuppressive ther-
apy in insulin-dependent diabetic peo-
ple (1). We have made microcapsules of
bariumalginateandshownthatinsulin-
producing porcine cells can function as
efﬁciently inside such capsules as when
nonencapsulated (2). Moreover, human
isletsplacedinthesecapsulesnormalize
blood glucose levels when engrafted in
diabetic mice (3,4). In the current
study, we transplanted four type 1 dia-
betic humans with encapsulated human
islets.
RESEARCH DESIGN AND
METHODS— Cadaver pancreata were
obtained with consent, and islets were iso-
lated by digestion with collagenase NB1
premium grade and neutral protease NB
(Serva, Germany). Islets were placed in
barium alginate microcapsules (2), and
their median average diameter from eight
islet preparations was 340 m (range
255–750).
Median viability of the encapsulated
islets, assessed with the ﬂuorescent dyes
carboxyﬂuorescein diacetate and pro-
pidium iodide (2), was 73% (range 60–
80%). Purity was 68% (range 50–88%),
and insulin content (2) was 1.1 mU/islet
equivalents (IEQs) (range 0.1–35). The
median stimulation index of the islets ex-
posed to 20 mmol/l glucose, compared
with 2.8 mmol/l glucose, for 1 h was 1.22
(range 1.0–2.4). The median number of
IEQs transplanted on each occasion was
178,200 (range 98,200–227,900). Con-
ditioned culture medium was free of mi-
crobial contamination.
Ofthe14diabeticpeoplescreenedfor
phase 1 of the clinical trial, 7 were selected
and4weretransplantedoveraperiodof19
months. The seven with long-standing type
1 diabetes had no endogenous insulin pro-
duction(noC-peptideinserumduringan
arginine tolerance test and none in 24-h
urine), BMI 25 kg/m
2, and weight 70
kg. Those transplanted had antibodies to
neitherGADnorisletcellsurfaceantigens
(ICA512). One person received four islet
infusions over 7 months with three in the
1st month; a second received two infu-
sions 10 months apart; and the other two
recipients received one infusion each (see
Tables A1 and A2 in the online appendix
availableathttp://care.diabetesjournals.org/
cgi/content/full/dc09-0744/DC1). Infu-
sions were carried out on an outpatient
basis in the Department of Medical Imag-
ing, Prince of Wales Hospital, Sydney,
Australia.
No immunosuppression was used,
but recipients did take both a mild anti-
inﬂammatory agent (Atorvastatin 20 mg)
andantioxidants(vitaminA50,000units,
vitamin B6 100 mg, and vitamin E 750
units) after each transplant. For the last
two islet infusions, exenatide 5 g b.i.d.
was administered in an attempt to en-
hance -cell survival and function.
Approval for all the procedures per-
formed was obtained from the Institutional
Human Research Ethics Committee.
RESULTS— C-peptide was detected
in urine on the 1st day after the islet infu-
sion (median 0.59 nmol/l [range 0.11–
1.79]; 0.15 nmol/mmol creatinine [range
0.06–0.25]) with levels declining there-
after and becoming undetectable at 1–4
weeks (median 10 days) later. Both blood
glucose levels and insulin requirements
were also lower on the 1st day after trans-
plantation by an average (means  SEM)
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but not thereafter. An arginine tolerance
test was carried out on the 7th day, and
plasma C-peptide was undetectable.
In the recipient of the four islet infu-
sions, urinary C-peptide was detected at 6
weeksafterthethirdinfusionandcontinues
toremaindetectableat2.5years.C-peptide
levels are 0.06–0.34 nmol/l or 0.02–0.06
nmol/mmol creatinine. The small amount
of insulin being produced did not alter in-
sulin requirements or glycemic control.
Tobetterunderstandwhatwasoccur-
ring in the transplanted capsules, a lapa-
roscopy was performed in the recipient of
the four islet infusions at 16 months after
the ﬁrst infusion. Large numbers of cap-
sules were found scattered throughout
the peritoneal cavity in clusters attached
to the parietal peritoneum (Fig. 1A),
spleen, omentum, and kidney. A biopsy
showed the capsules to be intact and sur-
rounded by ﬁbrous tissue containing thin-
walled capillaries with a mild histiocytic
response. Islets were necrotic (Fig. 1B).
Antibodies were detected to GAD
but not ICA512 in three recipients. The
titer became elevated 4 weeks after the
ﬁrst infusion in two of the recipients
and it was 14 weeks after the fourth in-
fusion in the third recipient. In all these
recipients, antibodies continue to re-
main detectable 1.12.5 years after the
initial infusion.
Cytotoxic antibodies were detected at
4 and 8 weeks after the ﬁrst infusion in
two patients, one who received four infu-
sions and the other a single infusion. The
titer, 56 and 32%, respectively, declined
with time but was still detectable when
lastmeasuredat1.9and0.6years,respec-
tively (titers of 19% for both).
Therewerenoseriousadverseevents.
Nausea did occur in the two recipients of
exenatide, and the medication was
stopped earlier than anticipated because
ofthissymptominoneperson.Therewas
a trend for blood glucose levels to be
lower when exenatide was administered,
probably because of delayed gastric emp-
tying since urinary C-peptide was some-
times undetectable. Wound infections
did not occur, and all recipients were dis-
chargedwithinanhourofthecompletion
of the infusion.
CONCLUSIONS — Phase 1 of the
trial shows that the infusion of encapsu-
lated human islets is safe, although cyto-
toxic antibodies can develop. All
recipientshadnormalrenalfunctionafter
several decades of type 1 diabetes, which
makes them extremely unlikely to ever
developrenaldysfunctionandpotentially
require a renal transplant. In such a situ-
ation, the occurrence of cytotoxic anti-
bodies is mostly of passing interest.
The laparoscopy performed on a re-
cipient of encapsulated human islets was
novel with the capsules intact and the is-
lets necrotic. This outcome is different
from that of the one other report (5) of a
laparoscopy performed in a human receiv-
ingencapsulatedinsulin-producingcells.In
that case, viable endocrine cells were ob-
servedintheencapsulatedneonatalporcine
cells 9 years after transplantation (5).
Loss of graft function within days of
transplantation was likely due to either
ischemic necrosis or an inﬂammatory
process, possibly initiated by ﬁbrinogen
adhering to the capsule surface (6). Cyto-
kines could enter the capsule through its
pores (250 kDa) and destroy the -cells.
Figure 1—Biopsy of the encapsulated human islets taken from the recipient of four islet infusions
(total of 779,000 IEQs) 16 months after the ﬁrst infusion. A: Clusters of capsules on parietal
peritoneum (black arrows indicate some of the many clusters). B: Higher magniﬁcation showing
necroticislets(N)insidecapsules(artifactuallydistortedbecauseofﬁxing)surroundedbyﬁbrous
tissuecontainingfewbloodvessels.(Ahigh-qualitydigitalrepresentationofthisﬁgureisavailable
in the online issue.)
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lastingforyearsintherecipientofthefour
infusions might be explained by a small
number of ductal cells in the graft differ-
entiating into -cells (7).
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